Spots Global Cancer Trial Database for A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Official Title: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Study ID: NCT05981703
Study Description
Brief Summary: This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
Southside Cancer Care, Miranda, New South Wales, Australia
Macquarie University, North Ryde, New South Wales, Australia
Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
Hubei Cancer Hospital, Wuhan, Hubei, China
The First Hospital of China Medical University Hunnan Branch, Shenyang, Liaoning, China
Jining No Peoples Hospital, Jining, Shandong, China
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Auckland City Hospital, Auckland, , New Zealand
Contact Details
Name: Study Director
Affiliation: BeiGene
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
